Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

166.99
+0.99000.60%
Post-market: 166.80-0.1900-0.11%19:46 EST
Volume:2.06M
Turnover:344.83M
Market Cap:10.15B
PE:-27.58
High:168.57
Open:166.12
Low:165.25
Close:166.00
52wk High:182.99
52wk Low:95.49
Shares:60.77M
Float Shares:58.65M
Volume Ratio:2.07
T/O Rate:3.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0558
EPS(LYR):9.06
ROE:-9.06%
ROA:4.88%
PB:2.56
PE(LYR):18.44

Loading ...

Jazz Pharmaceuticals to Present Phase 3 Zanidatamab Trial Results at Investor Webcast

Reuters
·
Dec 18

Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest

Simply Wall St.
·
Dec 15

Jazz Pharmaceuticals SVP Technical Operations Mary Elizabeth Henderson Reports Sale of Common Shares

Reuters
·
Dec 12

Jazz Pharmaceuticals Price Target Raised to $219.00/Share From $147.00 by Piper Sandler

Dow Jones
·
Dec 11

Jazz Pharmaceuticals SVP Chief Accounting Officer Patricia Carr Reports Disposal of Common Shares

Reuters
·
Dec 10

Jazz Pharmaceuticals Highlights New Epidiolex Data in Treatment-Resistant Epilepsies at AES 2025

Reuters
·
Dec 05

Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Reuters
·
Dec 03

Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher

Reuters
·
Nov 27

Director Heather Ann McSharry Reports Disposal of Jazz Pharmaceuticals plc Common Shares

Reuters
·
Nov 25

Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says

MT Newswires Live
·
Nov 25

Jazz Pharmaceuticals Cut to Neutral From Buy by UBS

Dow Jones
·
Nov 24

Jazz Pharmaceuticals downgraded to Neutral from Buy at UBS

TIPRANKS
·
Nov 24

Jazz Pharmaceuticals Plc : UBS Cuts to Neutral From Buy; Raises Target Price to $188 From $163

THOMSON REUTERS
·
Nov 24

A Look at Jazz Pharmaceuticals's Valuation After Landmark HERIZON-GEA-01 Ziihera Trial Results

Simply Wall St.
·
Nov 23

Jazz Pharmaceuticals EVP Robert Iannone Reports Sale of Common Shares

Reuters
·
Nov 20

Truist Adjusts Price Target on Jazz Pharmaceuticals Public to $220 From $205, Maintains Buy Rating

MT Newswires Live
·
Nov 19

Jazz Pharmaceuticals Plc : Truist Securities Raises Target Price to $220 From $205

THOMSON REUTERS
·
Nov 19

Jazz Pharmaceuticals to Join Citi's 2025 Global Healthcare Conference

Reuters
·
Nov 19

Truist ups Jazz Pharmaceuticals price target, says Ziihera is pipeline-in-a drug

TIPRANKS
·
Nov 19

U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler

Reuters
·
Nov 18